SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland
The serious, progressive kidney disease affects nearly 850 million people worldwide
Read More
Tag: Boehringer Ingelheim
Boehringer Ingelheim and Ochre Bio partner on liver disease in deal worth over $1bn
Chronic liver disease and associated cirrhosis account for one million deaths every year
Read More
New clinical study to advance development of treatments for liver cirrhosis
The £30m ADVANCE study is the most extensive study into liver disease worldwide
Read More
Shared vision for Boehringer Ingelheim and RetinAI
Companies will collaborate to boost novel treatments for individuals with geographic atrophy
Read More
NICE fails to recommend Boehringer Ingelheim and Lilly Alliance’s empagliflozin
The treatment has been developed to treat certain chronic heart failure patients and is approved elsewhere
Read More
Quantro and Boehringer Ingelheim collaborate on inhibitors
Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies
Read More
VisionHealth and Boehringer Ingelheim link up for asthma
The partnership will deliver digital therapy support for asthma and COPD patients
Read More
First treatment for adults across full spectrum of chronic heart failure
Largest unmet need in cardiovascular medicine finally receives approved therapy
Read More
Brain Training: BioMed X Institute collaborates with Boehringer Ingelheim
Sensor development project marks the fifth joint research effort between BioMed X with Boehringer Ingelheim
Read More
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of Jardiance in HFpEF patients
Read More
US approves Pradaxa as oral blood thinning med for children
First oral blood thinning drug approved for paediatric patients in the US
Read More
Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies
Agreement will leverage Enara’s novel Dark Antigen discovery platform
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
